Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumazenil for OCD
NCT00997087Phase 2Terminated
- Sponsor
- Parkway Medical Center
- Start
- Oct 2009
- Primary completion
- Dec 2012
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Flumazenil with Placebo (2 arms). Primary endpoint: Yale Brown Obsessive Compulsive Score at 12 weeks. Started Oct 2009; status: terminated.
02
Drugs
flumazenil
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT00997087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00997087.